ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans 11 Medical and Health Sciences 1109 Neurosciences 06 Biological Sciences 0604 Genetics

Olivia J. Conway, Minerva M Carrasquillo, Xue Wang, Jenny M. Bredenberg, Joseph S. Reddy, Samantha L. Strickland, Curtis S. Younkin, Jeremy D. Burgess, Mariet Allen, Sarah J. Lincoln, Thuy Nguyen, Kimberly G. Malphrus, Alexandra I. Soto, Ronald L. Walton, Bradley F Boeve, Ronald Carl Petersen, John A Lucas, Tanis Jill Ferman, William P. Cheshire, Jay A Van GerpenRyan J. Uitti, Zbigniew K Wszolek, Owen A Ross, Dennis W Dickson, Neill R Graff Radford, Nilufer Taner

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Rare coding variants ABI3-rs616338-T and PLCG2-rs72824905-G were identified as risk or protective factors, respectively, for Alzheimer's disease (AD). Methods: We tested the association of these variants with five neurodegenerative diseases in Caucasian case-control cohorts: 2742 AD, 231 progressive supranuclear palsy (PSP), 838 Parkinson's disease (PD), 306 dementia with Lewy bodies (DLB) and 150 multiple system atrophy (MSA) vs. 3351 controls; and in an African-American AD case-control cohort (181 AD, 331 controls). 1479 AD and 1491 controls were non-overlapping with a prior report. Results: Using Fisher's exact test, there was significant association of both ABI3-rs616338-T (OR = 1.41, p = 0.044) and PLCG2-rs72824905-G (OR = 0.56, p = 0.008) with AD. These OR estimates were maintained in the non-overlapping replication AD-control analysis, albeit at reduced significance (ABI3-rs616338-T OR = 1.44, p = 0.12; PLCG2-rs72824905-G OR = 0.66, p = 0.19). None of the other cohorts showed significant associations that were concordant with those for AD, although the DLB cohort had suggestive findings (Fisher's test: ABI3-rs616338-T OR = 1.79, p = 0.097; PLCG2-rs72824905-G OR = 0.32, p = 0.124). PLCG2-rs72824905-G showed suggestive association with pathologically-confirmed MSA (OR = 2.39, p = 0.050) and PSP (OR = 1.97, p = 0.061), although in the opposite direction of that for AD. We assessed RNA sequencing data from 238 temporal cortex (TCX) and 224 cerebellum (CER) samples from AD, PSP and control patients and identified co-expression networks, enriched in microglial genes and immune response GO terms, and which harbor PLCG2 and/or ABI3. These networks had higher expression in AD, but not in PSP TCX, compared to controls. This expression association did not survive adjustment for brain cell type population changes. Conclusions: We validated the associations previously reported with ABI3-rs616338-T and PLCG2-rs72824905-G in a Caucasian AD case-control cohort, and observed a similar direction of effect in DLB. Conversely, PLCG2-rs72824905-G showed suggestive associations with PSP and MSA in the opposite direction. We identified microglial gene-enriched co-expression networks with significantly higher levels in AD TCX, but not in PSP, a primary tauopathy. This co-expression network association appears to be driven by microglial cell population changes in a brain region affected by AD pathology. Although these findings require replication in larger cohorts, they suggest distinct effects of the microglial genes, ABI3 and PLCG2 in neurodegenerative diseases that harbor significant vs. low/no amyloid ß pathology.

Original languageEnglish (US)
Article number53
JournalMolecular Neurodegeneration
Volume13
Issue number1
DOIs
StatePublished - Oct 11 2018

Fingerprint

Biological Science Disciplines
Neurosciences
Neurodegenerative Diseases
African Americans
Alzheimer Disease
Progressive Supranuclear Palsy
Health
Multiple System Atrophy
Lewy Body Disease
Temporal Lobe
Tauopathies
Pathology
Genes
RNA Sequence Analysis
Brain
Amyloid
Cerebellum
Population
Parkinson Disease

Keywords

  • ABI3
  • African-American
  • Alzheimer's disease (AD)
  • Dementia with Lewy bodies (DLB)
  • Expression
  • Genetic association
  • Multiple system atrophy (MSA)
  • Parkinson's disease (PD)
  • PLCG2
  • Progressive supranuclear palsy (PSP)

ASJC Scopus subject areas

  • Molecular Biology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans 11 Medical and Health Sciences 1109 Neurosciences 06 Biological Sciences 0604 Genetics. / Conway, Olivia J.; Carrasquillo, Minerva M; Wang, Xue; Bredenberg, Jenny M.; Reddy, Joseph S.; Strickland, Samantha L.; Younkin, Curtis S.; Burgess, Jeremy D.; Allen, Mariet; Lincoln, Sarah J.; Nguyen, Thuy; Malphrus, Kimberly G.; Soto, Alexandra I.; Walton, Ronald L.; Boeve, Bradley F; Petersen, Ronald Carl; Lucas, John A; Ferman, Tanis Jill; Cheshire, William P.; Van Gerpen, Jay A; Uitti, Ryan J.; Wszolek, Zbigniew K; Ross, Owen A; Dickson, Dennis W; Graff Radford, Neill R; Taner, Nilufer.

In: Molecular Neurodegeneration, Vol. 13, No. 1, 53, 11.10.2018.

Research output: Contribution to journalArticle

Conway, Olivia J. ; Carrasquillo, Minerva M ; Wang, Xue ; Bredenberg, Jenny M. ; Reddy, Joseph S. ; Strickland, Samantha L. ; Younkin, Curtis S. ; Burgess, Jeremy D. ; Allen, Mariet ; Lincoln, Sarah J. ; Nguyen, Thuy ; Malphrus, Kimberly G. ; Soto, Alexandra I. ; Walton, Ronald L. ; Boeve, Bradley F ; Petersen, Ronald Carl ; Lucas, John A ; Ferman, Tanis Jill ; Cheshire, William P. ; Van Gerpen, Jay A ; Uitti, Ryan J. ; Wszolek, Zbigniew K ; Ross, Owen A ; Dickson, Dennis W ; Graff Radford, Neill R ; Taner, Nilufer. / ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans 11 Medical and Health Sciences 1109 Neurosciences 06 Biological Sciences 0604 Genetics. In: Molecular Neurodegeneration. 2018 ; Vol. 13, No. 1.
@article{d8b2759fb8a44fb6af7d79fd933a761f,
title = "ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans 11 Medical and Health Sciences 1109 Neurosciences 06 Biological Sciences 0604 Genetics",
abstract = "Background: Rare coding variants ABI3-rs616338-T and PLCG2-rs72824905-G were identified as risk or protective factors, respectively, for Alzheimer's disease (AD). Methods: We tested the association of these variants with five neurodegenerative diseases in Caucasian case-control cohorts: 2742 AD, 231 progressive supranuclear palsy (PSP), 838 Parkinson's disease (PD), 306 dementia with Lewy bodies (DLB) and 150 multiple system atrophy (MSA) vs. 3351 controls; and in an African-American AD case-control cohort (181 AD, 331 controls). 1479 AD and 1491 controls were non-overlapping with a prior report. Results: Using Fisher's exact test, there was significant association of both ABI3-rs616338-T (OR = 1.41, p = 0.044) and PLCG2-rs72824905-G (OR = 0.56, p = 0.008) with AD. These OR estimates were maintained in the non-overlapping replication AD-control analysis, albeit at reduced significance (ABI3-rs616338-T OR = 1.44, p = 0.12; PLCG2-rs72824905-G OR = 0.66, p = 0.19). None of the other cohorts showed significant associations that were concordant with those for AD, although the DLB cohort had suggestive findings (Fisher's test: ABI3-rs616338-T OR = 1.79, p = 0.097; PLCG2-rs72824905-G OR = 0.32, p = 0.124). PLCG2-rs72824905-G showed suggestive association with pathologically-confirmed MSA (OR = 2.39, p = 0.050) and PSP (OR = 1.97, p = 0.061), although in the opposite direction of that for AD. We assessed RNA sequencing data from 238 temporal cortex (TCX) and 224 cerebellum (CER) samples from AD, PSP and control patients and identified co-expression networks, enriched in microglial genes and immune response GO terms, and which harbor PLCG2 and/or ABI3. These networks had higher expression in AD, but not in PSP TCX, compared to controls. This expression association did not survive adjustment for brain cell type population changes. Conclusions: We validated the associations previously reported with ABI3-rs616338-T and PLCG2-rs72824905-G in a Caucasian AD case-control cohort, and observed a similar direction of effect in DLB. Conversely, PLCG2-rs72824905-G showed suggestive associations with PSP and MSA in the opposite direction. We identified microglial gene-enriched co-expression networks with significantly higher levels in AD TCX, but not in PSP, a primary tauopathy. This co-expression network association appears to be driven by microglial cell population changes in a brain region affected by AD pathology. Although these findings require replication in larger cohorts, they suggest distinct effects of the microglial genes, ABI3 and PLCG2 in neurodegenerative diseases that harbor significant vs. low/no amyloid {\ss} pathology.",
keywords = "ABI3, African-American, Alzheimer's disease (AD), Dementia with Lewy bodies (DLB), Expression, Genetic association, Multiple system atrophy (MSA), Parkinson's disease (PD), PLCG2, Progressive supranuclear palsy (PSP)",
author = "Conway, {Olivia J.} and Carrasquillo, {Minerva M} and Xue Wang and Bredenberg, {Jenny M.} and Reddy, {Joseph S.} and Strickland, {Samantha L.} and Younkin, {Curtis S.} and Burgess, {Jeremy D.} and Mariet Allen and Lincoln, {Sarah J.} and Thuy Nguyen and Malphrus, {Kimberly G.} and Soto, {Alexandra I.} and Walton, {Ronald L.} and Boeve, {Bradley F} and Petersen, {Ronald Carl} and Lucas, {John A} and Ferman, {Tanis Jill} and Cheshire, {William P.} and {Van Gerpen}, {Jay A} and Uitti, {Ryan J.} and Wszolek, {Zbigniew K} and Ross, {Owen A} and Dickson, {Dennis W} and {Graff Radford}, {Neill R} and Nilufer Taner",
year = "2018",
month = "10",
day = "11",
doi = "10.1186/s13024-018-0289-x",
language = "English (US)",
volume = "13",
journal = "Molecular Neurodegeneration",
issn = "1750-1326",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans 11 Medical and Health Sciences 1109 Neurosciences 06 Biological Sciences 0604 Genetics

AU - Conway, Olivia J.

AU - Carrasquillo, Minerva M

AU - Wang, Xue

AU - Bredenberg, Jenny M.

AU - Reddy, Joseph S.

AU - Strickland, Samantha L.

AU - Younkin, Curtis S.

AU - Burgess, Jeremy D.

AU - Allen, Mariet

AU - Lincoln, Sarah J.

AU - Nguyen, Thuy

AU - Malphrus, Kimberly G.

AU - Soto, Alexandra I.

AU - Walton, Ronald L.

AU - Boeve, Bradley F

AU - Petersen, Ronald Carl

AU - Lucas, John A

AU - Ferman, Tanis Jill

AU - Cheshire, William P.

AU - Van Gerpen, Jay A

AU - Uitti, Ryan J.

AU - Wszolek, Zbigniew K

AU - Ross, Owen A

AU - Dickson, Dennis W

AU - Graff Radford, Neill R

AU - Taner, Nilufer

PY - 2018/10/11

Y1 - 2018/10/11

N2 - Background: Rare coding variants ABI3-rs616338-T and PLCG2-rs72824905-G were identified as risk or protective factors, respectively, for Alzheimer's disease (AD). Methods: We tested the association of these variants with five neurodegenerative diseases in Caucasian case-control cohorts: 2742 AD, 231 progressive supranuclear palsy (PSP), 838 Parkinson's disease (PD), 306 dementia with Lewy bodies (DLB) and 150 multiple system atrophy (MSA) vs. 3351 controls; and in an African-American AD case-control cohort (181 AD, 331 controls). 1479 AD and 1491 controls were non-overlapping with a prior report. Results: Using Fisher's exact test, there was significant association of both ABI3-rs616338-T (OR = 1.41, p = 0.044) and PLCG2-rs72824905-G (OR = 0.56, p = 0.008) with AD. These OR estimates were maintained in the non-overlapping replication AD-control analysis, albeit at reduced significance (ABI3-rs616338-T OR = 1.44, p = 0.12; PLCG2-rs72824905-G OR = 0.66, p = 0.19). None of the other cohorts showed significant associations that were concordant with those for AD, although the DLB cohort had suggestive findings (Fisher's test: ABI3-rs616338-T OR = 1.79, p = 0.097; PLCG2-rs72824905-G OR = 0.32, p = 0.124). PLCG2-rs72824905-G showed suggestive association with pathologically-confirmed MSA (OR = 2.39, p = 0.050) and PSP (OR = 1.97, p = 0.061), although in the opposite direction of that for AD. We assessed RNA sequencing data from 238 temporal cortex (TCX) and 224 cerebellum (CER) samples from AD, PSP and control patients and identified co-expression networks, enriched in microglial genes and immune response GO terms, and which harbor PLCG2 and/or ABI3. These networks had higher expression in AD, but not in PSP TCX, compared to controls. This expression association did not survive adjustment for brain cell type population changes. Conclusions: We validated the associations previously reported with ABI3-rs616338-T and PLCG2-rs72824905-G in a Caucasian AD case-control cohort, and observed a similar direction of effect in DLB. Conversely, PLCG2-rs72824905-G showed suggestive associations with PSP and MSA in the opposite direction. We identified microglial gene-enriched co-expression networks with significantly higher levels in AD TCX, but not in PSP, a primary tauopathy. This co-expression network association appears to be driven by microglial cell population changes in a brain region affected by AD pathology. Although these findings require replication in larger cohorts, they suggest distinct effects of the microglial genes, ABI3 and PLCG2 in neurodegenerative diseases that harbor significant vs. low/no amyloid ß pathology.

AB - Background: Rare coding variants ABI3-rs616338-T and PLCG2-rs72824905-G were identified as risk or protective factors, respectively, for Alzheimer's disease (AD). Methods: We tested the association of these variants with five neurodegenerative diseases in Caucasian case-control cohorts: 2742 AD, 231 progressive supranuclear palsy (PSP), 838 Parkinson's disease (PD), 306 dementia with Lewy bodies (DLB) and 150 multiple system atrophy (MSA) vs. 3351 controls; and in an African-American AD case-control cohort (181 AD, 331 controls). 1479 AD and 1491 controls were non-overlapping with a prior report. Results: Using Fisher's exact test, there was significant association of both ABI3-rs616338-T (OR = 1.41, p = 0.044) and PLCG2-rs72824905-G (OR = 0.56, p = 0.008) with AD. These OR estimates were maintained in the non-overlapping replication AD-control analysis, albeit at reduced significance (ABI3-rs616338-T OR = 1.44, p = 0.12; PLCG2-rs72824905-G OR = 0.66, p = 0.19). None of the other cohorts showed significant associations that were concordant with those for AD, although the DLB cohort had suggestive findings (Fisher's test: ABI3-rs616338-T OR = 1.79, p = 0.097; PLCG2-rs72824905-G OR = 0.32, p = 0.124). PLCG2-rs72824905-G showed suggestive association with pathologically-confirmed MSA (OR = 2.39, p = 0.050) and PSP (OR = 1.97, p = 0.061), although in the opposite direction of that for AD. We assessed RNA sequencing data from 238 temporal cortex (TCX) and 224 cerebellum (CER) samples from AD, PSP and control patients and identified co-expression networks, enriched in microglial genes and immune response GO terms, and which harbor PLCG2 and/or ABI3. These networks had higher expression in AD, but not in PSP TCX, compared to controls. This expression association did not survive adjustment for brain cell type population changes. Conclusions: We validated the associations previously reported with ABI3-rs616338-T and PLCG2-rs72824905-G in a Caucasian AD case-control cohort, and observed a similar direction of effect in DLB. Conversely, PLCG2-rs72824905-G showed suggestive associations with PSP and MSA in the opposite direction. We identified microglial gene-enriched co-expression networks with significantly higher levels in AD TCX, but not in PSP, a primary tauopathy. This co-expression network association appears to be driven by microglial cell population changes in a brain region affected by AD pathology. Although these findings require replication in larger cohorts, they suggest distinct effects of the microglial genes, ABI3 and PLCG2 in neurodegenerative diseases that harbor significant vs. low/no amyloid ß pathology.

KW - ABI3

KW - African-American

KW - Alzheimer's disease (AD)

KW - Dementia with Lewy bodies (DLB)

KW - Expression

KW - Genetic association

KW - Multiple system atrophy (MSA)

KW - Parkinson's disease (PD)

KW - PLCG2

KW - Progressive supranuclear palsy (PSP)

UR - http://www.scopus.com/inward/record.url?scp=85054991963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054991963&partnerID=8YFLogxK

U2 - 10.1186/s13024-018-0289-x

DO - 10.1186/s13024-018-0289-x

M3 - Article

C2 - 30326945

AN - SCOPUS:85054991963

VL - 13

JO - Molecular Neurodegeneration

JF - Molecular Neurodegeneration

SN - 1750-1326

IS - 1

M1 - 53

ER -